Guru Ownership Trend
Guru Analysis for Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 2 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $1.39 M.
Top institutional holders include Renaissance Technologies (RenTech) and Paul Tudor Jones.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $20.55 M net outflow during the quarter.
Recent activity highlights Renaissance Technologies (RenTech) who opened a new position.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Corvus Pharmaceuticals, Inc. (CRVS)
Major holders include Renaissance Technologies (RenTech) ($1.19 M), Paul Tudor Jones ($402,237). According to the latest reported data, 2 tracked investment managers collectively hold approximately 108,804 shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $20.55 M, with 2 managers increasing positions and 1 managers reducing holdings.
During the most recent reporting period, 0 managers trimmed their positions, while 1 fully exited CRVS. The total reported sell value was $22.14 M.
Yes, 2 managers opened new positions in CRVS, and 0 increased their existing holdings. The total reported buy value was $1.59 M.